A Phase 2 interventional study of gemcitabine and paclitaxel in Breast Cancer, sponsored by Eli Lilly and Company. Completed at 18 sites in 6 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2010-03-02.
Sponsored by Eli Lilly and Company · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 373 studies testing paclitaxel in Breast Neoplasms — 40 open to participants now, 60 under way, 13 of them phase 3. Paclitaxel · Breast Neoplasms.
Among the 373 studies testing paclitaxel in Breast Neoplasms, this one is the 93rd largest by enrollment of the 361 interventional ones that give a count, is one of 17 that started in 2005, is one of 205 in phase 2, and was the 68th registered.
14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.
Browse Breast Neoplasms studies →40 of the 373 studies testing paclitaxel in Breast Neoplasms are open now, in 12 countries. Recruiting first, the newest first:
Zhejiang Cancer Hospital · Sites in China
Ages 18+
Liu Shu · Sites in China
Ages 18–70 · Women only
RenJi Hospital · Sites in China
Ages 18–70 · Women only
Second Affiliated Hospital, School of Medicine, Zhejiang University · Sites in China
Ages 18–75 · Women only
Jazz Pharmaceuticals · Sites in United States, Germany, Italy and 1 more country
Ages 18+
By country, each count listing its studies:
Paclitaxel: first FDA approval 1992 (TAXOL), first EMA approval 1999. What it is approved for, and how studies give it, is on its page →
Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
373 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 74 · Phase 2 249 · Phase 3 69 · Phase 4 10
First in 1994; this study’s year is marked. 17 started in 2005.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 147 is above the median of 72 across 10,908 interventional studies indexed under Breast Neoplasms.
Median enrollment 60 across the 361 interventional studies. Of the 254 that completed or were terminated, 125 (49%) have results posted.
This tab as a report to print or save as PDF → With an account.
66 of 373 have an industry lead sponsor. The 10 most frequent:
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
88 studies in Breast Neoplasms by Eli Lilly and Company: 7 open now, 22 under way, 8 of them phase 3. Of 61 finished, 40 (66%) have results posted.
Among the 88 studies in Breast Neoplasms by Eli Lilly and Company, this one is the 39th largest by enrollment of the 80 interventional ones that give a count, is one of 6 that started in 2005, is one of 41 in phase 2, and was the 11th registered.
Eli Lilly and Company’s Breast Neoplasms studies by the year they started, since 1998.
16 of the studies testing paclitaxel in Breast Neoplasms that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05183126University of Michigan Rogel Cancer CenterPharmacokinetic Study of Skeletal Muscle Area-based Paclitaxel Infusion in Patients With Cancer | 2026-11 |
| NCT03125928Fox Chase Cancer CenterClinical Trial of Atezolizumab With Paclitaxel, Trastuzumab, and Pertuzumab in Patients With Metastatic HER-2 Positive Breast Cancer | 2026-12 |
| NCT07283692RenJi HospitalNeoadjuvant Serplulimab Plus Weekly Paclitaxel and Carboplatin in TNBC (Neo-SERPENT) | 2026-12 |
| NCT07580833Health Hope PharmaA Study to Investigate the Effect of Food on the Bioavailability of Oral Paclitaxel Administered With Encequidar in Participants With Advanced Solid Tumors | 2026-12 |
| NCT05383196Antonio Giordano, MDOnvansertib + Paclitaxel In TNBC | 2026-12-15 |
Add all 16 to your calendar (.ics) → With an account.
Among the 373 studies testing paclitaxel in Breast Neoplasms, from their registry updates:
Among Eli Lilly and Company’s 88 in Breast Neoplasms:
This tab as a report to print or save as PDF → With an account.
The gemcitabine-paclitaxel and gemcitabine-platinum combinations have shown promise in the treatments of MBC; however, the optimal dosing schedules for these combinations have not yet been determined. The primary objective of this study is to compare the response rates of the gemcitabine-paclitaxel, gemcitabine-carboplatin, and gemcitabine-cisplatin combinations when administered on a biweekly schedule in metastatic breast cancer.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
gemcitabine: 2500 milligrams per square meter (mg/m2), intravenous (IV), every 14 days x 8 cycles. paclitaxel: 150 mg/m2, IV, every 14 days x 8 cycles.
Drug: gemcitabine · Drug: paclitaxel
gemcitabine: 2500 milligrams per square meter (mg/m2), intravenous (IV), every 14 days x 8 cycles. carboplatin: Area Under the Curve (AUC) 2.5, IV, every 14 days x 8 cycles.
Drug: gemcitabine · Drug: carboplatin
gemcitabine: 2500 milligrams per square meter (mg/m2), intravenous (IV), every 14 days x 8 cycles. cisplatin: 50 mg/m2, IV, every 14 days x 8 cycles
Drug: gemcitabine · Drug: cisplatin
2500 milligrams per square meter (mg/m2), intravenous (IV), every 14 days x 8 cycles
Also known as: LY188011, Gemzar
150 mg/m2, IV, every 14 days x 8 cycles
Area Under the Curve (AUC) 2.5, IV, every 14 days x 8 cycles
50 mg/m2, IV, every 14 days x 8 cycles
Best Overall Response
Response using Response Evaluation Criteria In Solid Tumors (RECIST) criteria. Complete Response=disappearance of all target lesions; Partial Response=30% decrease in sum of longest diameter of target lesions; Progressive Disease=20% increase in sum of longest diameter of target lesions; Stable Disease=small changes that do not meet above criteria.
Time frame: baseline to measured progressive disease (tumor assessments were performed every 4 cycles during study therapy, or 3 months during post-therapy until disease progression, death or up to 24 months after randomization)
Number of Participants With a Time to Treatment Failure (TTTF) Event
TTTF event was defined as documented disease progression, death on study, start of non-protocol-specified anticancer therapy, or therapy discontinuation due to toxicity. TTTF for patients who were still participating in study without treatment failure at time of analysis were treated as censored at date of last tumor assessment. TTTF for patients who had discontinued from therapy for reasons other than toxicity and who did not experience treatment failure prior to therapy discontinuation were treated as censored on day of study discontinuation.
Time frame: randomization to date of documented disease progression, death on study, start of non-protocol-specified anticancer therapy, or therapy discontinuation due to toxicity, whichever occurred first (up to 6 months)
Progression Free Survival (PFS)
PFS was defined as the time from randomizaton to the date of documented disease progression or death on study, whichever occurred first. PFS for participants who discontinued from the study or who had not progressed at the time of analysis were treated as censored at the date of the last tumor assessment.
Time frame: baseline to measured progressive disease or death (tumor assessments were performed every 4 cycles during study therapy, or 3 months during post-therapy until disease progression, death, or up to 24 months after randomization)
Duration of Response
Duration of response was measured from time of first documentation of complete response (disappearance of all target lesions) or partial response (30% decrease in sum of longest diameter of target lesions), until date of PFS. Duration of response was censored on day of last tumor assessment for patients who had not progressed or who had discontinued study at time of analysis, and for cases where investigator determined patient had progressive disease and discontinued study therapy and/or started a new, non-protocol-specified anti-cancer therapy before documented disease progression.
Time frame: time of response to progressive disease or death (tumor assessments were performed every 4 cycles during study therapy, or 3 months during post-therapy until disease progression, death, or up to 24 months after randomization)
Overall Survival
Overall survival time is defined as the time from the date of randomization to date of death due to any cause. Survival time is censored at the date of last contact for patients who are still alive or lost to follow-up.
Time frame: baseline to date of death from any cause (up to 34 months)
| Milestone | Gemcitabine + Paclitaxel | Gemcitabine + Carboplatin | Gemcitabine + Cisplatin |
|---|---|---|---|
| Started | 49 | 47 | 51 |
| Received at least one dose of study drug | 49 | 47 | 50 |
| Completed | 12 | 17 | 12 |
| Not completed | 37 | 30 | 39 |
| Withdrew: Death | 26 | 23 | 29 |
| Withdrew: Lost to follow-up | 7 | 5 | 5 |
| Withdrew: Withdrawal by subject | 4 | 2 | 3 |
| Withdrew: Sponsor decision | 0 | 0 | 1 |
| Withdrew: Screen failure | 0 | 0 | 1 |
Response using Response Evaluation Criteria In Solid Tumors (RECIST) criteria. Complete Response=disappearance of all target lesions; Partial Response=30% decrease in sum of longest diameter of target lesions; Progressive Disease=20% increase in sum of longest diameter of target lesions; Stable Disease=small changes that do not meet above criteria.
| participants | Gemcitabine + Paclitaxel | Gemcitabine + Carboplatin | Gemcitabine + Cisplatin |
|---|---|---|---|
| Complete Response (CR) | 1 | 0 | 1 |
| Partial Response (PR) | 12 | 8 | 7 |
| Stable Disease (SD) | 17 | 25 | 29 |
| Progressive Disease (PD) | 14 | 11 | 11 |
| Early Death from Other Causes | 1 | 2 | 0 |
| Unknown | 4 | 1 | 3 |
TTTF event was defined as documented disease progression, death on study, start of non-protocol-specified anticancer therapy, or therapy discontinuation due to toxicity. TTTF for patients who were still participating in study without treatment failure at time of analysis were treated as censored at date of last tumor assessment. TTTF for patients who had discontinued from therapy for reasons other than toxicity and who did not experience treatment failure prior to therapy discontinuation were treated as censored on day of study discontinuation.
| participants | Gemcitabine + Paclitaxel | Gemcitabine + Carboplatin | Gemcitabine + Cisplatin |
|---|---|---|---|
| Number of Participants With a Time to Treatment Failure (TTTF) Event | 15 | 21 | 21 |
PFS was defined as the time from randomizaton to the date of documented disease progression or death on study, whichever occurred first. PFS for participants who discontinued from the study or who had not progressed at the time of analysis were treated as censored at the date of the last tumor assessment.
| months | Gemcitabine + Paclitaxel | Gemcitabine + Carboplatin | Gemcitabine + Cisplatin |
|---|---|---|---|
| Progression Free Survival (PFS) | 4.8 (4.2 to 7.0) | 4.3 (3.7 to 5.9) | 4.8 (3.7 to 8.1) |
Duration of response was measured from time of first documentation of complete response (disappearance of all target lesions) or partial response (30% decrease in sum of longest diameter of target lesions), until date of PFS. Duration of response was censored on day of last tumor assessment for patients who had not progressed or who had discontinued study at time of analysis, and for cases where investigator determined patient had progressive disease and discontinued study therapy and/or started a new, non-protocol-specified anti-cancer therapy before documented disease progression.
| months | Gemcitabine + Paclitaxel | Gemcitabine + Carboplatin | Gemcitabine + Cisplatin |
|---|---|---|---|
| Duration of Response | 5.8 (4.9 to 8.1) | 3.2 (1.9 to 5.0) | 5.1 (2.9 to 5.1) |
Overall survival time is defined as the time from the date of randomization to date of death due to any cause. Survival time is censored at the date of last contact for patients who are still alive or lost to follow-up.
| months | Gemcitabine + Paclitaxel | Gemcitabine + Carboplatin | Gemcitabine + Cisplatin |
|---|---|---|---|
| Overall Survival | 15.5 (0.361 to 33.84) | 22.8 (1.413 to 26.12) | 20.1 (1.413 to 27.83) |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Gemcitabine + Paclitaxel | — | 5/49 (10.2%) | 48/49 (98%) |
| Gemcitabine + Carboplatin | — | 3/47 (6.4%) | 46/47 (97.9%) |
| Gemcitabine + Cisplatin | — | 0/50 (0%) | 50/50 (100%) |
| Event | Gemcitabine + Paclitaxel | Gemcitabine + Carboplatin | Gemcitabine + Cisplatin |
|---|---|---|---|
| NeutropeniaBlood and lymphatic system disorders | 0/49 | 1/47 | 0/50 |
| ThrombocytopeniaBlood and lymphatic system disorders | 1/49 | 1/47 | 0/50 |
| Hepatic failureHepatobiliary disorders | 0/49 | 1/47 | 0/50 |
| PneumoniaInfections and infestations | 0/49 | 1/47 | 0/50 |
| PyelonephritisInfections and infestations | 0/49 | 1/47 | 0/50 |
| SepsisInfections and infestations | 0/49 | 1/47 | 0/50 |
| Haemoglobin decreasedInvestigations | 0/49 | 1/47 | 0/50 |
| Renal failure acuteRenal and urinary disorders | 0/49 | 1/47 | 0/50 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 1/49 | 1/47 | 0/50 |
| Pleural effusionRespiratory, thoracic and mediastinal disorders | 0/49 | 1/47 | 0/50 |
| Event | Gemcitabine + Paclitaxel | Gemcitabine + Carboplatin | Gemcitabine + Cisplatin |
|---|---|---|---|
| NauseaGastrointestinal disorders | 19/49 | 25/47 | 39/50 |
| VomitingGastrointestinal disorders | 12/49 | 22/47 | 31/50 |
| AlopeciaSkin and subcutaneous tissue disorders | 25/49 | 16/47 | 22/50 |
| Neutrophil count decreasedInvestigations | 22/49 | 14/47 | 21/50 |
| Alanine aminotransferase increasedInvestigations | 18/49 | 20/47 | 8/50 |
| Haemoglobin decreasedInvestigations | 15/49 | 18/47 | 18/50 |
| Platelet count decreasedInvestigations | 7/49 | 18/47 | 7/50 |
| FatigueGeneral disorders | 18/49 | 17/47 | 15/50 |
| White blood cell count decreasedInvestigations | 17/49 | 13/47 | 13/50 |
| AnorexiaMetabolism and nutrition disorders | 11/49 | 15/47 | 8/50 |
| Age Continuous(years) | Gemcitabine + Paclitaxel | Gemcitabine + Carboplatin | Gemcitabine + Cisplatin | Total |
|---|---|---|---|---|
| Mean | 49.8 ± 8.8 | 46.0 ± 6.9 | 49.2 ± 10.3 | 48.4 ± 8.9 |
| Sex: Female, Male(Participants) | Gemcitabine + Paclitaxel | Gemcitabine + Carboplatin | Gemcitabine + Cisplatin | Total |
|---|---|---|---|---|
| Female | 49 | 47 | 51 | 147 |
| Male | 0 | 0 | 0 | 0 |
| Region of Enrollment(participants) | Gemcitabine + Paclitaxel | Gemcitabine + Carboplatin | Gemcitabine + Cisplatin | Total |
|---|---|---|---|---|
| Mexico | 1 | 2 | 3 | 6 |
| Brazil | 5 | 5 | 4 | 14 |
| Turkey | 5 | 2 | 4 | 11 |
| China | 25 | 25 | 26 | 76 |
| Korea, Republic of | 5 | 5 | 6 | 16 |
| India | 8 | 8 | 8 | 24 |
| Eastern Cooperative Oncology Group Performance Status(participants) | Gemcitabine + Paclitaxel | Gemcitabine + Carboplatin | Gemcitabine + Cisplatin | Total |
|---|---|---|---|---|
| 0 - Fully Active | 22 | 29 | 26 | 77 |
| 1 - Ambulatory, Restricted Strenuous Activity | 27 | 18 | 24 | 69 |
| Missing Data | 0 | 0 | 1 | 1 |
| Menopausal Status(participants) | Gemcitabine + Paclitaxel | Gemcitabine + Carboplatin | Gemcitabine + Cisplatin | Total |
|---|---|---|---|---|
| Pre-Menopausal | 11 | 16 | 13 | 40 |
| Peri Menopausal | 4 | 4 | 4 | 12 |
| Post Menopausal | 34 | 26 | 33 | 93 |
| Missing Data | 0 | 1 | 1 | 2 |
| Pathological Diagnosis(participants) | Gemcitabine + Paclitaxel | Gemcitabine + Carboplatin | Gemcitabine + Cisplatin | Total |
|---|---|---|---|---|
| Adenocarcinoma | 1 | 2 | 2 | 5 |
| Carcinoma, Infiltrating Ductal | 42 | 40 | 45 | 127 |
| Carcinoma, Infiltrating Lobular | 6 | 4 | 2 | 12 |
| Carcinoma, Undifferentiated | 0 | 1 | 0 | 1 |
| Comedocarcinoma | 0 | 0 | 1 | 1 |
| Missing Data | 0 | 0 | 1 | 1 |
| Race/Ethnicity(participants) | Gemcitabine + Paclitaxel | Gemcitabine + Carboplatin | Gemcitabine + Cisplatin | Total |
|---|---|---|---|---|
| African | 1 | 0 | 1 | 2 |
| Caucasian | 8 | 6 | 7 | 21 |
| East Asian | 30 | 30 | 32 | 92 |
| Hispanic | 2 | 3 | 3 | 8 |
| West Asian (West Indian) | 8 | 8 | 8 | 24 |
The record gives a start of Mar 2005, a primary completion of Aug 2008 and a completion of Nov 2009. It does not say whether these dates are actual or estimated.
Results were first posted in Aug 2009, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2010. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Paclitaxel · Carboplatin · Cisplatin